TorEx Lung Perfusion System
Traferox Technologies, Inc. · Decision date Jul 15, 2026
What did the FDA approve?
FDA records P250025 as an original PMA application. The recorded decision is approval, dated Jul 15, 2026.
FDA approval order statement
The TorEx Lung Perfusion System is indicated for use in continuous normothermic machine perfusion of donor lungs, initially deemed unsuitable for transplantation, during which time the ex vivo function of the lungs can be reassessed for transplantation in adults. The TorEx Lung Perfusion System includes a mobile cart with embedded software, single-use sterile Organ Chamber and Cannulae set and is used with TorEx Lung Perfusate solution to perform ex vivo lung perfusion for up to 6 hours.Note: The TorEx System is used to evaluate the quality of donated lungs, but the final determination of the suitability of the lungs for transplant remains with the transplanting surgeon.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jul 15, 2026
Regulatory record facts
- Identifier
- P250025
- Regulatory pathway
- Premarket approval application
- Applicant
- Traferox Technologies, Inc.
- Product code
- PHO
- Decision code
- APPR
- Decision date
- Jul 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.
- Applicant
- Traferox Technologies, Inc.
- Product code
- PHO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250025 received
Application receipt date recorded by FDA.
P250025 · FDA decision
APPR
P250025/S001 · Related supplement
TorEx Lung Perfusion System; TorEx Lung Perfusate
P250025/S002 · Related supplement
TorEx Lung Perfusion System; TorEx Lung Perfusate
Timeline entries are records held by MedtechLedger for P250025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code PHO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LungFX DeviceP240033/S001 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
LungFX DeviceP240033/S002 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
XPS with Steen Solution PerfusateP180014/S014 | Xvivo Perfusion, Inc. | PMA supplement | Sep 16, 2026 | FDA |
LungFX deviceP240033 | Lung Bioengineering, Inc. | PMA approval | Jun 22, 2026 | FDA |
| Xvivo Perfusion, Inc. | PMA approval | Apr 26, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Traferox Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3505 Laird Rd., Unit 16, Mississauga, L5L 5Y7
Sources and methodology
- Original FDA record: P250025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




